Amyris, Inc. (AMRS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Amyris, Inc. (AMRS) trades at $0.05 with AI Score 44/100 (Grade C). Amyris, Inc. is a synthetic biotechnology company focused on developing and manufacturing sustainable ingredients and consumer products. Sector: Basic materials.
Last analyzed: May 10, 2026Analyst Coverage for AMRS: AMRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMRS against Basic Materials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMRS: the 1 perspectives are evenly split.
Amyris, Inc. (AMRS) Materials & Commodity Exposure
Amyris, Inc. is a synthetic biotechnology company specializing in clean health and beauty, and flavors and fragrance markets. It distinguishes itself through the development and sale of sustainable ingredients and consumer products under brands like Biossance and Purecane, targeting environmentally conscious consumers and industries seeking sustainable alternatives.
What Is the Investment Thesis for AMRS?
Amyris presents a compelling investment thesis centered on its innovative synthetic biotechnology platform and expanding portfolio of sustainable consumer brands. The company's focus on clean beauty, personal care, and flavors and fragrances aligns with growing consumer demand for sustainable and ethically sourced products. Key value drivers include the expansion of its existing brands, the launch of new products, and the increasing adoption of its ingredients by other companies. However, Amyris operates in a competitive landscape and faces challenges related to scaling production, managing costs, and achieving profitability. The company's negative profit margin of -198.6% highlights the need for improved financial performance. Successful execution of its growth strategy and efficient management of its operations are crucial for realizing the company's long-term potential.
Based on FMP financials and quantitative analysis
AMRS Key Highlights
- Operates in the clean health and beauty, and flavors and fragrance markets, aligning with growing consumer demand for sustainable products.
- Offers a diverse portfolio of consumer brands, including Biossance, Pipette, and Purecane, targeting different segments of the sustainable products market.
- Supplies ingredients to other companies in the flavor and fragrance, nutrition, and cosmetics industries, providing a diversified revenue stream.
- Gross margin of 4.1% indicates potential for improvement through increased efficiency and economies of scale.
- Collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine represents a potential growth opportunity in the healthcare sector.
Who Are AMRS's Competitors?
AMRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IFF International Flavors & Fragrances Inc. | $77.94 | +0.55% | $19.90B | 52 |
| DSM BNY Mellon Strategic Municipal Bond Fund, Inc. | $6.13 | +0.25% | 303M | 48 |
| HGRAF HydroGraph Clean Power Inc. | $5.00 | +0.81% | $1.70B | 69 |
| LWLG Lightwave Logic, Inc. | $9.59 | -4.48% | 2B | 69 |
| COOSF Carbios SAS | $8.61 | +0.00% | $145.26M | 69 |
| NVZMY Novozymes A/S | $59.99 | -0.37% | $27.97B | 62 |
| MITUY Mitsui Chemicals, Inc. | $11.21 | +0.00% | $4.13B | 49 |
| ASGLY AGC Inc. | $8.71 | +0.58% | $9.25B | 49 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMRS's Key Strengths?
- Innovative synthetic biotechnology platform.
- Strong portfolio of consumer brands.
- Focus on sustainable and ethically sourced ingredients.
- Vertically integrated operations.
What Are AMRS's Weaknesses?
- Negative profit margin.
- High operating expenses.
- Reliance on a limited number of key ingredients.
- Relatively small market share compared to larger competitors.
What Could Drive AMRS Stock Higher?
- Launch of new products under existing brands.
- Expansion of distribution channels for consumer products.
- Increasing adoption of Amyris's ingredients by other companies.
- Strategic partnerships and collaborations to expand market reach.
What Are the Key Risks for AMRS?
- Fluctuations in raw material prices.
- Changes in consumer preferences.
- Regulatory changes affecting the biotechnology industry.
- Competition from larger and more established companies.
- Negative profit margin and high operating expenses.
What Are the Growth Opportunities for AMRS?
- Expansion of Existing Brands: Amyris has the opportunity to expand its existing brands, such as Biossance and Purecane, through new product launches, increased distribution, and targeted marketing campaigns. The global market for clean beauty products is projected to reach $22 billion by 2024, providing a significant growth runway for Biossance and other clean beauty brands.
- New Product Development: Amyris can leverage its synthetic biotechnology platform to develop new and innovative ingredients and products for various markets. The company's expertise in engineering microorganisms allows it to create sustainable alternatives to traditional ingredients, addressing the growing demand for eco-friendly solutions in the flavor and fragrance, nutrition, and cosmetics industries.
- Strategic Partnerships and Collaborations: Amyris can pursue strategic partnerships and collaborations with other companies to expand its reach and access new markets. Collaborating with established players in the consumer goods, food and beverage, and cosmetics industries can accelerate the adoption of Amyris's ingredients and products.
- Geographic Expansion: Amyris has the opportunity to expand its geographic presence, particularly in Asia and South America, where demand for sustainable products is growing rapidly. Establishing distribution networks and partnerships in these regions can drive significant revenue growth.
- Increased Adoption of Sustainable Ingredients: Amyris can capitalize on the increasing demand for sustainable ingredients by expanding its supply agreements with other companies. As more companies commit to reducing their environmental footprint, the demand for Amyris's bio-based ingredients is expected to increase.
What Opportunities Does AMRS Have?
- Expanding demand for sustainable products.
- New product development and innovation.
- Strategic partnerships and collaborations.
- Geographic expansion.
What Threats Does AMRS Face?
- Competition from larger and more established companies.
- Fluctuations in raw material prices.
- Changes in consumer preferences.
- Regulatory changes affecting the biotechnology industry.
What Are AMRS's Competitive Advantages?
- Proprietary synthetic biotechnology platform for developing sustainable ingredients.
- Established brands with a loyal customer base in the clean beauty and personal care markets.
- Strong relationships with ingredient customers in various industries.
- Vertically integrated operations, from ingredient development to product manufacturing and distribution.
What Does AMRS Do?
Amyris, Inc., founded in 2003 and headquartered in Emeryville, California, is a synthetic biotechnology company focused on creating sustainable ingredients for various markets. Originally named Amyris Biotechnologies, Inc., the company rebranded in 2010 to reflect its expanding focus. Amyris utilizes synthetic biology to engineer microorganisms that convert plant-based sugars into high-value ingredients. These ingredients are then used in a range of products, including clean beauty, personal care, health and wellness consumer products, as well as ingredients for the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. Amyris's portfolio includes a diverse range of brands such as Biossance (clean beauty), Pipette (baby care), Purecane (zero-calorie sweetener), Terasana (skincare), Costa Brazil (sustainable beauty), OLIKA (hand sanitizers), Rose Inc. (color cosmetics), and JVN (haircare). These brands cater to the growing demand for sustainable and ethically sourced products. In addition to its consumer brands, Amyris also supplies ingredients to other companies in the flavor and fragrance, nutrition, and cosmetics industries. Amyris also has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine.
What Products and Services Does AMRS Offer?
- Develops and manufactures sustainable ingredients using synthetic biotechnology.
- Sells clean beauty, personal care, and health and wellness consumer products.
- Offers ingredients to the flavor and fragrance industry.
- Provides ingredients for the nutrition, food, and beverage markets.
- Markets products under brands like Biossance, Pipette, and Purecane.
- Collaborates on the development of a COVID-19 vaccine.
How Does AMRS Make Money?
- Develops and manufactures sustainable ingredients through synthetic biology.
- Sells finished consumer products directly to consumers through e-commerce and retail channels.
- Supplies ingredients to other companies in the flavor and fragrance, nutrition, and cosmetics industries.
- Generates revenue through product sales and ingredient supply agreements.
What Industry Does AMRS Operate In?
Amyris operates within the specialty chemicals industry, which is experiencing increasing demand for sustainable and bio-based alternatives. The global market for specialty chemicals is estimated to be worth hundreds of billions of dollars, with a growing segment focused on green and sustainable solutions. Amyris competes with both traditional chemical companies and other synthetic biotechnology firms. The company's focus on clean beauty and personal care positions it within a rapidly expanding market segment driven by increasing consumer awareness of environmental and health issues.
Who Are AMRS's Key Customers?
- Consumers seeking clean beauty, personal care, and health and wellness products.
- Companies in the flavor and fragrance industry looking for sustainable ingredients.
- Businesses in the nutrition, food, and beverage markets seeking bio-based alternatives.
- Other cosmetics companies utilizing Amyris's ingredients in their products.
AMRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AMRS Latest News
-
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
benzinga · Aug 17, 2023
-
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
benzinga · Aug 10, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · May 16, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · May 15, 2023
AMRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMRS.
Price Targets
Wall Street price target analysis for AMRS.
AMRS MoonshotScore
What does this score mean?
The MoonshotScore rates AMRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Monday
Leadership: Hermanus Kieftenbeld
Chief Executive Officer
Hermanus Kieftenbeld is the Chief Executive Officer of Amyris, Inc. His background includes extensive experience in the biotechnology and consumer products industries. Prior to joining Amyris, he held leadership positions at various companies, focusing on strategy, operations, and business development. His expertise spans across multiple areas, including manufacturing, supply chain management, and commercialization of innovative products. He is responsible for overseeing Amyris's overall strategy and operations.
Track Record: Since becoming CEO, Hermanus Kieftenbeld has focused on streamlining Amyris's operations and expanding its portfolio of sustainable consumer brands. He has overseen the launch of new products and the expansion of the company's distribution network. Key milestones under his leadership include strategic partnerships and collaborations aimed at accelerating the adoption of Amyris's ingredients and products.
What Investors Ask About Amyris, Inc. (AMRS) — Basic Materials
What does Amyris, Inc. do?
Amyris, Inc. is a synthetic biotechnology company that develops and manufactures sustainable ingredients and consumer products. The company uses synthetic biology to engineer microorganisms that convert plant-based sugars into high-value ingredients. These ingredients are then used in a range of products, including clean beauty, personal care, health and wellness consumer products, as well as ingredients for the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. Amyris markets its products under various brands, including Biossance, Pipette, and Purecane.
What do analysts say about AMRS stock?
Analyst coverage of Amyris, Inc. (AMRS) is mixed, reflecting the company's potential and challenges. Some analysts highlight the company's innovative technology and growing portfolio of sustainable consumer brands as key growth drivers. Others express concerns about the company's financial performance, including its negative profit margin and high operating expenses. Valuation metrics vary depending on the analyst's assumptions about future growth and profitability. The consensus view is that Amyris has significant potential, but successful execution of its growth strategy is crucial for realizing its long-term value.
What are the main risks for AMRS?
Amyris, Inc. faces several key risks, including competition from larger and more established companies in the specialty chemicals and consumer products industries. Fluctuations in raw material prices, particularly sugar, can impact the company's cost of goods sold and profitability. Changes in consumer preferences and demand for sustainable products can also affect the company's revenue growth. Regulatory changes affecting the biotechnology industry and the use of genetically modified organisms pose another potential risk. The company's negative profit margin and high operating expenses also present ongoing financial challenges.
What are the key factors to evaluate for AMRS?
Amyris, Inc. (AMRS) holds an AI score of 44/100 (low). Not financial advice.
How frequently does AMRS data refresh on this page?
AMRS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AMRS's recent stock price performance?
Amyris, Inc. (AMRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative synthetic biotechnology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AMRS overvalued or undervalued right now?
Valuing Amyris, Inc. (AMRS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AMRS?
Before investing in Amyris, Inc. (AMRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent reported data.